Perioperative FLOT versus neoadjuvant CROSS for esophageal adenocarcinoma: real-world validation of the ESOPEC trial from the German Cancer Registry Group

Objective: To validate the findings of the ESOPEC trial, which demonstrated the superiority of perioperative 5-FU, leucovorin, oxaliplatin, docetaxel (FLOT) chemotherapy over Chemoradiotherapy for Esophageal Cancer Followed by Surgery Study (CROSS) in patients with resectable locally advanced esophageal and gastroesophageal junction adenocarcinoma in a population-based real-world setting. Methods: This retrospective cohort study, using clinical registry data provided by the German Cancer Registry Group of the Society of German Tumor Centers, included patients with adenocarcinoma of the esophagus or gastroesophageal junction (cT1 cN + cM0 or cT2–4 cNx cM0) who received neoadjuvant FLOT or CROSS. Propensity score matching was employed to balance baseline characteristics. The primary endpoint was overall survival (OS). Secondary endpoints were achievement of pathological complete response (pCR), perioperative mortality, and long-term recurrence-free survival. Results: After propensity score matching, 1088 patients were included. There were no significant differences between the FLOT and CROSS groups in terms of baseline tumor characteristics. After surgery, CROSS was associated with lower ypT stages ( P = 0.011) and a tendency toward higher pCR (15.8% vs. 12.6%; P = 0.221). Despite these advantages, FLOT was associated with longer median OS (28.1 vs. 22.1 months; P = 0.0016) compared to CROSS. Moreover, FLOT was associated with lower 90-day postoperative mortality (5.1% vs. 10%; P = 0.036). The crude proportion of documented distant recurrence in the follow-up was lower after FLOT than after CROSS (28.3% vs. 35.1%; P = 0.019). Conclusion: Perioperative chemotherapy using FLOT was associated with longer OS, lower 90-day mortality, and a lower crude proportion of documented distant recurrence when compared with neoadjuvant chemoradiotherapy CROSS in locally advanced adenocarcinoma of the esophagus and gastroesophageal junction; these real-world findings are directionally consistent with the ESOPEC trial.

Authors

Institutions

Publication Details

Journal
International Journal of Surgery
Published
2026-11-12
DOI
https://doi.org/10.1097/js9.0000000000005717
Primary Topic
Esophageal Cancer Research and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Perioperative FLOT versus neoadjuvant CROSS for esophageal adenocarcinoma: real-world validation of the ESOPEC trial from the German Cancer Registry Group

Stefan Rolf Benz, Tobias Keck, Thaer S. A. Abdalla, Michael Schweigert et al.
International Journal of Surgery
Esophageal Cancer Research and Treatment
article

Perioperative FLOT versus neoadjuvant CROSS for esophageal adenocarcinoma: real-world validation of the ESOPEC trial from the German Cancer Registry Group

Stefan Rolf Benz, Tobias Keck, Thaer S. A. Abdalla, Michael Schweigert, Simone Faißt, Ahmed Bedir, Justus Baecker, Fabian Reinwald, Kees Kleihues-van Tol, Richard Hummel, Sylke Ruth Zeißig, Markus Kist, Jannis Duhn, Stephan Kersting, Monika Klinkhammer‐Schalke, Michael Thomaschewski, Constanze Schneider, Jessica Isabel Selig, Bianca Franke, Ulrich Friedrich Wellner
article en

Abstract

Objective: To validate the findings of the ESOPEC trial, which demonstrated the superiority of perioperative 5-FU, leucovorin, oxaliplatin, docetaxel (FLOT) chemotherapy over Chemoradiotherapy for Esophageal Cancer Followed by Surgery Study (CROSS) in patients with resectable locally advanced esophageal and gastroesophageal junction adenocarcinoma in a population-based real-world setting. Methods: This retrospective cohort study, using clinical registry data provided by the German Cancer Registry Group of the Society of German Tumor Centers, included patients with adenocarcinoma of the esophagus or gastroesophageal junction (cT1 cN + cM0 or cT2–4 cNx cM0) who received neoadjuvant FLOT or CROSS. Propensity score matching was employed to balance baseline characteristics. The primary endpoint was overall survival (OS). Secondary endpoints were achievement of pathological complete response (pCR), perioperative mortality, and long-term recurrence-free survival. Results: After propensity score matching, 1088 patients were included. There were no significant differences between the FLOT and CROSS groups in terms of baseline tumor characteristics. After surgery, CROSS was associated with lower ypT stages ( P = 0.011) and a tendency toward higher pCR (15.8% vs. 12.6%; P = 0.221). Despite these advantages, FLOT was associated with longer median OS (28.1 vs. 22.1 months; P = 0.0016) compared to CROSS. Moreover, FLOT was associated with lower 90-day postoperative mortality (5.1% vs. 10%; P = 0.036). The crude proportion of documented distant recurrence in the follow-up was lower after FLOT than after CROSS (28.3% vs. 35.1%; P = 0.019). Conclusion: Perioperative chemotherapy using FLOT was associated with longer OS, lower 90-day mortality, and a lower crude proportion of documented distant recurrence when compared with neoadjuvant chemoradiotherapy CROSS in locally advanced adenocarcinoma of the esophagus and gastroesophageal junction; these real-world findings are directionally consistent with the ESOPEC trial.

International Journal of Surgery
University of Würzburg (DE), Universitätsmedizin Greifswald (DE), Technical University of Applied Sciences Lübeck (DE), University of Lübeck (DE), Otto-von-Guericke-Universität Magdeburg (DE)
Good health and well-being
Esophageal Cancer Research and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon